• About
• Links
• Contact
• Sitemap
• 

Melanoma - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

The report is an essential source of information and analysis on the global Melanoma disease market. The report identifies the key trends shaping and driving the global Melanoma disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Melanoma disease sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

Annualized global Melanoma disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes oxidative stress inducer targets Bcl-2 receptor Mitotic Inhibitor MAGE antigen Immunomodulatory effects T-cell enhancer anti-CTLA4 Peptide Viral vaccine Peptide encapsulated vaccine Combinations.

Analysis of the current and future market competition in the global Melanoma disease market. Key market players covered are Oncolytics Biotech., Bristol-Myers Squibb, Swedish Orphan International AB Bayer Schering Pharma AG, Genta Incorporated, Schering-Plough, GlaxoSmithKline and Abraxis BioScience.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Melanoma disease.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Melanoma disease market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Melanoma disease market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global Melanoma disease market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Global Melanoma Market: Market Characterization

• 2.1 Overview
• 2.2 Melanoma Market Size
• 2.3 Melanoma Market Forecast and Compound Annual Growth Rate
• 2.4 Drivers and Barriers for the Melanoma Market
  • 2.4.1 Drivers for the Melanoma Market
  • 2.4.2 Barriers for the Melanoma Market
• 2.5 Key Takeaway

3 Global Melanoma Market: Competitive Assessment

• 3.1 Overview
• 3.2 Strategic Competitor Assessment
• 3.3 Product Profile for the Major Marketed Products in the Melanoma Market
  • 3.3.1 DTIC - Dome (Dacarbazine)
  • 3.3.2 Proleukin (Aldesleukin)
  • 3.3.3 Intro A (interferon alpha 2b)
• 3.4 Key Take Away

4 Global Melanoma Market: Pipeline Assessment

• 4.1 Overview
• 4.2 Strategic Pipeline Assessment
• 4.3 Melanoma Market – Promising Drugs under Clinical Development
• 4.4 Molecule Profile for Promising Drugs under Clinical Development
  • 4.4.1 PegIntron (Pegylated interferon alfa-2b)
  • 4.4.2 Multiferon (Human Albumin)
  • 4.4.3 Oncovex GMCSF (HSV DNA Vaccine)
  • 4.4.4 Ipilimumab (MDX-010, MDX-101)
  • 4.4.5 Allovectin-7
• 4.5 Melanoma Market – Clinical Pipeline by Mechanism of Action
  • 4.5.1 Melanoma Market – Phase III Clinical Pipeline
  • 4.5.2 Melanoma Market – Phase II Clinical Pipeline
  • 4.5.3 Melanoma Market – Phase I Clinical Pipeline
  • 4.5.4 Melanoma Market – Preclinical Pipeline
  • 4.5.5 Melanoma Market – Discovery Phase Pipeline
  • 4.5.6 Melanoma Market – List of Terminated Clinical Trials
• 4.6 Key Takeaway

5 Global Melanoma Market: Implications for Future Market Competition

6 Global Melanoma Market: Future Players in Melanoma Market

• 6.1 Introduction
• 6.2 Abraxis BioScience
  • 6.2.1 Company Overview
  • 6.2.2 Business Description
• 6.3 GlaxoSmithKline
  • 6.3.1 Overview
  • 6.3.2 Business Description
• 6.4 Schering-Plough
  • 6.4.1 Overview
  • 6.4.2 Business Description
• 6.5 Genta Incorporated
  • 6.5.1 Overview
  • 6.5.2 Business Description
• 6.6 Swedish Orphan International AB
  • 6.6.1 Overview
• 6.7 Bristol-Myers Squibb
  • 6.7.1 Overview
  • 6.7.2 Business Description
• 6.8 Bayer Schering Pharma AG
  • 6.8.1 Overview
  • 6.8.2 Business Description
• 6.9 Oncolytics Biotech
  • 6.9.1 Introduction
  • 6.9.2 Business Discription

7 Melanoma Market: Appendix

• 7.1 Definitions
• 7.2 Acronyms
• 7.3 Research Methodology
  • 7.3.1 Coverage
  • 7.3.2 Secondary Research
  • 7.3.3 Forecasting
  • 7.3.4 Primary Research
  • 7.3.5 Expert Panel Validation
• 7.4 Contact Us
• 7.5 Disclaimer
• 7.6 Sources

1.1 List of Tables

• Table 1: Global Melanoma Market Revenue ($m) Historical, 2000-2008
• Table 2: Global Melanoma Market Revenue ($m) Forecast Figures, 2008-2015
• Table 3: Major Marketed Products Comparison in Melanoma Market, 2009
• Table 4: Melanoma Market – Most Promising Drugs Under Clinical Development, 2009
• Table 5: Melanoma Market – Phase III Clinical Pipeline,2009
• Table 6: Melanoma Market – Phase II Clinical Pipeline, 2009
• Table 7: Melanoma Market – Phase I Clinical Pipeline, 2009
• Table 8: Melanoma Market – Preclinical Pipeline, 2009
• Table 9: Melanoma Market – Discovery Pipeline, 2009
• Table 10: Melanoma Therapeutics – List of Terminated Clinical Trials, 2009

1.2 List of Figures

• Figure 1: Global Melanoma Market Forecast 2000–2015
• Figure 2: Opportunity and Unmet Need in the Melanoma Market, 2009
• Figure 3: Strategic Competitor Assessment, 2009
• Figure 4: Technology Trends Analytics Frame Work, 2009
• Figure 5: Technology Trends Analytics Frame Work – Description, 2009
• Figure 6: Melanoma Market – Clinical Pipeline by Mechanism of Action, 2009
• Figure 7: Melanoma Market – Clinical Pipeline by Phase of Development, 2009
• Figure 8: Implications for Future Market Competition in the Melanoma Disease Market, 2009
• Figure 9: Melanoma Therapeutics Market – Clinical Pipeline by Company, 2009
• Figure 10: Methodology
• Figure 11: Market Forecasting Model

Other users found this report page using the following search terms: Melanoma melanoma market melanomamarket melanomamarketsize drugs size drug melanomadrugmarket pipeline development

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.